Drug Trial Radar · NCT01872897
Compound Sodium Alginate Double Action Chewable Tablets 4-hour Esophageal pH Study in GERD Patients
Last checked: Nov 20, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Jul 2, 2013
Primary completion
Dec 2013
Study completion Dec 2013
Sponsor
- Lead sponsor
- Reckitt Benckiser Healthcare (UK) LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jun 7, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to assess the effectiveness of the Compound Sodium Alginate Double Action Chewable Tablets compared to placebo on acidic reflux events into the esophagus in patients diagnosed with Gastroesophageal Reflux Disease (GERD).
Conditions
- Gastroesophageal Reflux Disease
Interventions
Sodium Alginate Double Action Chewable TabletsDrug
4 tablets as a single dose
PlaceboDrug
4 tablets as a single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Time During the 4-hour Post-dosing Period With pH Below pH 4Time frame: 0 to 4 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
RB Investigational Sites
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.